نتایج جستجو برای: proguanil

تعداد نتایج: 315  

Journal: :British journal of clinical pharmacology 1996
N E Basci A Bozkurt S Kortunay A Isimer A Sayal S O Kayaalp

The oxidation of proguanil was studied in 89 unrelated healthy Turkish volunteers after administration of proguanil (single dose, 200 mg, orally). Based on the distribution of the ratio of proguanil to cycloguanil excreted in urine, and using an antimode value of 15, the prevalence of poor metabolizers in a Turkish population was estimated to be 5.6% (95% confidence interval 2.0%-17.3%) which w...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002
Mark D Lacy Jason D Maguire Mazie J Barcus Judith Ling Michael J Bangs Robert Gramzinski Hasan Basri Priyanto Sismadi Gerri B Miller Jeffrey D Chulay David J Fryauff Stephen L Hoffman J Kevin Baird

Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for ...

Journal: :Antimicrobial agents and chemotherapy 1999
I K Srivastava A B Vaidya

A combination of atovaquone and proguanil has been found to be quite effective in treating malaria, with little evidence of the emergence of resistance when atovaquone was used as a single agent. We have examined possible mechanisms for the synergy between these two drugs. While proguanil by itself had no effect on electron transport or mitochondrial membrane potential (DeltaPsim), it significa...

Journal: :The Journal of infectious diseases 2014
Rachida Tahar Talleh Almelli Camille Debue Vincent Foumane Ngane Joseph Djaman Allico Solange Whegang Youdom Leonardo K Basco

BACKGROUND Artemisinin-based combination therapies (ACTs) are recommended for the treatment of acute uncomplicated falciparum malaria in many malaria-endemic countries. Despite the emergence of artemisinin resistance, few alternative non-ACTs, including atovaquone-proguanil, are currently available. METHODS Plasmodium falciparum-infected Cameroonian children ≤5 years old (n = 338) were random...

Journal: :The Journal of pharmacology and experimental therapeutics 1997
C Funck-Brentano L Becquemont A Lenevu A Roux P Jaillon P Beaune

Both the antimalarial prodrug proguanil and the gastric proton pump inhibitor omeprazole are substrates for cytochrome P450 (CYP)2C19 and CYP3A. However, the relative contribution of each enzyme to proguanil bioactivation to cycloguanil and to the metabolism of omeprazole, as well as their potential to interact, remains to be examined. The bioactivation of proguanil to its active metabolite cyc...

Journal: :The Journal of infectious diseases 1997
F E de Alencar C Cerutti R R Durlacher M Boulos F P Alves W Milhous L W Pang

The purpose of this study was to compare an experimental regimen of atovaquone plus proguanil with the standard regimen of quinine plus tetracycline for the treatment of uncomplicated falciparum malaria. The study was designed as an open, randomized study of men presenting with symptoms of uncomplicated malaria and thick-smear slide confirmation of parasitemia (1000-100,000 ring forms/microL). ...

Journal: :British medical journal 1970
A S Sagoe

Forty-three patients with an initial diagnosis of tropical splenomegaly syndrome were placed on long-term proguanil therapy. All patients who failed to respond to proguanil and who were adequately followed up developed identifiable disease, usually malignant lymphoma or chronic lymphatic leukaemia. In patients who responded to proguanil IgM values were always very high and phytohaemagglutinin (...

Journal: :BMJ 1993
J C Wetsteyn A de Geus

OBJECTIVES Confirmation of breakthroughs in three different malaria chemoprophylactic regimens (chloroquine 300 mg weekly and proguanil 100 mg daily; chloroquine 300 mg weekly and proguanil 200 mg daily; proguanil 200 mg daily) and assessment of compliance. DESIGN Prospective, randomised multicentre trial. SETTING Five vaccination centres in the Netherlands. SUBJECTS Dutch travellers to e...

Journal: :BMJ 2003
Patricia Schlagenhauf Alois Tschopp Richard Johnson Hans D Nothdurft Bernhard Beck Eli Schwartz Markus Herold Bjarne Krebs Olivia Veit Regina Allwinn Robert Steffen

OBJECTIVE To compare the tolerability of malaria chemoprophylaxis regimens in non-immune travellers. DESIGN Randomised, double blind, study with placebo run-in phase. SETTING Travel clinics in Switzerland, Germany, and Israel. MAIN OUTCOME MEASURE Proportion of participants in each treatment arm with subjectively moderate or severe adverse events. PARTICIPANTS 623 non-immune travellers ...

2015
Rasaq Olaosebikan Kolade Ernest Kalifa Bojang Olugbenga Mokuolu Andrea M. Rehman Muna Affara Davis Nwakanma Jean-René Kiechel Taofik Ogunkunle Tope Olagunju Rukayat Murtala Peter Omefe Tosin Lambe Surajudeen Bello Olayinka Ibrahim Benedict Olorunsola Ayotade Ojuawo Brian Greenwood Paul Milligan

BACKGROUND Malaria prophylaxis is recommended for persons with sickle cell disease (SCD), but the value of this has been questioned. The aim of this study was to find out whether intermittent preventive treatment (IPT) with a fixed-dose combination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) was more effective than daily proguanil for malaria prevention ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید